

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|             |                   |                   |              |
|-------------|-------------------|-------------------|--------------|
| Applicant:  | YOU <i>et al.</i> | Confirmation No.: | 2928         |
| Appln. No.: | 10/595,576        | Group Art Unit:   | 1656         |
| Date Filed: | 2006-04-28        | Examiner:         | MOORE, W. W. |

TITLE: THROMBIN-LIKE RECOMBINANT BATROXOBIN EXPRESSED BY  
PICHIA SP. AND PRODUCTION METHOD THEREOF

**COVER LETTER ACCOMPANYING IDS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please find submitted herewith an Information Disclosure Statement (IDS) calling various documents to the attention of the USPTO. Each of the cited materials are set forth on the accompanying Form PTO/SB/08a; and copies of the cited foreign patent documents and non-patent literature are enclosed, in accordance with USPTO practice. In addition, an International Search Report (ISR) and International Preliminary Report on Patentability (IPRP) received for parent International Application PCT/KR2003/002318 are also submitted with the present IDS, and are cited in the above-noted Form PTO/SB/08a as non-patent literature. The items cited in this IDS include the following:

1. People's Republic of China Patent Application Publication No. 1370833 A to AN *et al.*, which was published in Chinese on September 25, 2002, which was referenced in the above-noted ISR and also in the IPRP as document D1, and for which an English-

language translation of the Abstract is submitted herewith;

2. a scientific journal article to ITOH *et al.* titled *Molecular cloning and sequence analysis of cDNA for batroxobin, a thrombin-like snake venom enzyme*, which was published March 5, 1987, in J. Biol. Chem., Vol. 262, No. 7, at pages 3132—3135, and which was referenced in the above-noted ISR and also in the IPRP as document D2;
3. a scientific journal article to ZHANG *et al.* titled *Ren xian rong mei yuan K1-3 ji yin de ke long, biao da he chan wu de chun hua ji kang yan huo xing fen xi [Cloning and expression of kringle 1-3 gene of human plasminogen and the purification and bioactivity of its expressed product]*, which was published in Chinese on September 1, 2002, in the journal Sheng Wu Gong Cheng Xue Bao [Chinese Journal of Biotechnology], Vol. 18, No. 5, at pages 593—596, which was referenced in the above-noted IPRP as document D3, and for which an English-language translation of the Abstract is also submitted herewith;
4. Japanese Laid-open Patent Application 平 2 - 1 2 4 0 9 2 A to MAEDA *et al.*, which was published in Japanese on May 11, 1990, which was referenced in the above-noted ISR, and for which an English-language translation of the Abstract is submitted herewith;
5. a scientific journal article to GUO *et al.* titled *Cloning and Functional Expression of the Mucrosobin Protein, a  $\beta$ -Fibrinogenase of Trimeresurus mucrosquamatus (Taiwan Habu)*, which was published in 2001 in the journal Protein Expression and Purification, Vol. 23, at pages 483—490, and which was cited in the above-noted ISR;
6. Republic of Korea Patent 10-0796360 B1 to YOU *et al.*, which was registered by the Korean Intellectual Property Office (KIPO) on January 14, 2007, and which is related to

the present US application as a sibling Republic of Korea national phase of International Application PCT/KR2003/002318;

7. Republic of Korea Patent Application Publication 10-2002-0064787 A, which was published August 9, 2002, as a Republic of Korea national phase of International Application PCT/KR2000/00809, and which is included under heading (56) at the front page of above-noted Republic of Korea Patent No. 10-0796360 B1, thereby being identified as a document that was considered by KIPO during the examination of that sibling application;
8. US Patent No. 7,033,788 B1 to CHUNG *et al.*, which issued April 25, 2006, as a US national phase of above-noted International Application PCT/KR2000/00809, and which names at least one inventor in common with the present application;
9. US Patent Application Publication 2005/0032189 A1 to CHUNG *et al.*, which was published February 10, 2005, and which corresponds to above-cited US Patent No. 7,033,788;
10. International Application Publication WO 2002/014488 A1 to CHUNG *et al.*, corresponding to International Application PCT/KR2000/00809, which is the parent of above-noted US Patent No. 7,033,788 B1; and
11. a scientific journal article to DEMPFLÉ *et al.* titled *Analysis of fibrin formation and proteolysis during intravenous administration of ancrod*, which was published October 15, 2000, in the journal Blood, Vol. 96, No. 8, at pages 2793—2802, and which is referenced in the “Background Art” section of the Specification of the present application.

As an initial matter, the Applicant thanks the Examiner for the courtesy of the telephone consultations extended to the Applicant's representative, Ryan Rafferty, in advance of issuing a first action on the merits. During the telephone discussions, the Examiner noted that an International Preliminary Report on Patentability (IPRP) had been issued for the parent International Application, and that it may therefore be advisable to promptly file an IDS for this application submitting any relevant art cited in the IPRP.

In view of the Examiner's comments, and because a first action on the merits has not yet been issued for this application, the present IDS is submitted without an accompanying certification or fee under 37 CFR § 1.17. As an aside, the Applicant regrets any inconvenience that may have been caused by delay in submitting the present IDS. Nonetheless, if a certification and/or additional fee payment is deemed necessary, the Examiner is respectfully requested to again contact Applicant's representative via telephone so that the necessary papers can be promptly provided.

With regard to the items cited in this IDS, the relevance of the documents referenced in the above-noted ISR and IPRP is set forth by the International Examiner therein, applying PCT regulations to the claims of parent International Application PCT/KR2003/002318.

Accordingly, the Examiner is respectfully requested to acknowledge consideration of the documents cited in this IDS by initialing the appropriate entries in the accompanying Form PTO/SB/08 and returning a copy of the initialed and signed Form to the Applicant with the next Office communication. It is noted that a copy of the cited US patents and pre-grant application publication is omitted in view of preferred USPTO practice. Nonetheless, the Examiner is respectfully invited to contact Applicant's representative if any copies of these documents are needed.

If there should be any questions or comments regarding this IDS, the Office is respectfully requested to contact Applicant's representatives at the below-listed telephone number.

Respectfully submitted,

/Ryan M. Rafferty/

Ryan Rafferty  
Reg. No. 55,556

*April 23, 2008*

**The Rafferty Patent Law Firm**  
5641 Burke Centre PKWY, Suite 100  
BURKE, VA 22015-2259  
Tel.: +1-703-250-3091  
Fax: +1-626-549-2008  
mail@raffertyfirm.com